Cantor Fitzgerald Reaffirms Overweight Rating for Kura Oncology (NASDAQ:KURA)

Cantor Fitzgerald restated their overweight rating on shares of Kura Oncology (NASDAQ:KURA - Free Report) in a research note published on Wednesday morning, Benzinga reports.

A number of other research firms have also recently weighed in on KURA. Stifel Nicolaus cut Kura Oncology from a "buy" rating to a "hold" rating and lowered their price objective for the stock from $26.00 to $19.00 in a research report on Monday, October 14th. Lifesci Capital raised Kura Oncology to a "strong-buy" rating in a report on Tuesday, October 22nd. UBS Group started coverage on shares of Kura Oncology in a report on Thursday, October 24th. They set a "buy" rating and a $27.00 price objective on the stock. JMP Securities reiterated a "market outperform" rating and issued a $32.00 target price on shares of Kura Oncology in a research note on Monday, August 12th. Finally, Wedbush restated an "outperform" rating and set a $37.00 price target on shares of Kura Oncology in a research note on Monday. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $28.83.

Kura Oncology Trading Up 1.8 %

Shares of NASDAQ KURA traded up $0.32 during trading hours on Wednesday, hitting $17.84. 1,446,633 shares of the company traded hands, compared to its average volume of 592,695. The company's 50 day moving average price is $18.95 and its 200 day moving average price is $20.02. The company has a debt-to-equity ratio of 0.02, a quick ratio of 14.94 and a current ratio of 14.94. Kura Oncology has a 12 month low of $8.17 and a 12 month high of $24.17.

Kura Oncology (NASDAQ:KURA - Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.59) earnings per share for the quarter, beating the consensus estimate of ($0.63) by $0.04. During the same quarter in the prior year, the company posted ($0.53) EPS. The firm's revenue was up .0% on a year-over-year basis. Sell-side analysts expect that Kura Oncology will post -2.46 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. increased its position in shares of Kura Oncology by 0.7% in the 1st quarter. Vanguard Group Inc. now owns 4,065,903 shares of the company's stock valued at $86,726,000 after purchasing an additional 28,212 shares during the last quarter. Avoro Capital Advisors LLC boosted its stake in Kura Oncology by 29.2% during the 1st quarter. Avoro Capital Advisors LLC now owns 3,850,000 shares of the company's stock worth $82,120,000 after purchasing an additional 870,000 shares during the period. Armistice Capital LLC grew its holdings in shares of Kura Oncology by 14.7% during the second quarter. Armistice Capital LLC now owns 2,350,000 shares of the company's stock worth $48,386,000 after buying an additional 302,000 shares during the last quarter. Artal Group S.A. increased its stake in Kura Oncology by 8.6% in the 1st quarter. Artal Group S.A. now owns 1,919,884 shares of the company's stock valued at $40,951,000 after buying an additional 151,828 shares during the period. Finally, Assenagon Asset Management S.A. raised its stake in shares of Kura Oncology by 50.1% during the 2nd quarter. Assenagon Asset Management S.A. now owns 1,731,577 shares of the company's stock worth $35,653,000 after buying an additional 577,732 shares in the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.